## PATENT COOPERATION TREATY

n the ERNATIONAL SEARCHING AUTHORITY To: PCT WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/GB2005/000112 14.01.2005 14.01.2004 International Patent Classification (IPC) or both national classification and IPC C07F9/48, C07F17/02, B01J31/00 Applicant STYLACATS LIMITED This opinion contains indications relating to the following items: 1. Box No. I Basis of the opinion ☐ Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA: **Authorized Officer** 

<u>g</u>

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Richter, H .

Telephone No. +49 89 2399-8539



DITOT AVAILABLE COT

## WRITTEN OPINION OF THE CERNATIONAL SEARCHING AUTHORITY

International application No. PCT/GB2005/000112

_	Box No	o. I Basis of the opinion	
1.	With re	gard to the language, this opinion has been established on the basis of the international application in guage in which it was filed, unless otherwise indicated under this item.	
	iar	is opinion has been established on the basis of a translation from the original language into the following iguage—, which is the language of a translation furnished for the purposes of international search or relation for the purposes of international search or relations.	
2.	With re	gard to any nucleotide and/or amino acid sequence disclosed in the international application and ary to the claimed invention, this opinion has been established on the basis of:	
	a. type	of material:	
		a sequence listing	
		table(s) related to the sequence listing	
	b. form	b. format of material:	
		in written format	
,		in computer readable form	
	c. time	of filing/furnishing:	
		contained in the international application as filed.	
		filed together with the international application in computer readable form.	
		furnished subsequently to this Authority for the purposes of search.	
3.	CO	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto s been filed or furnished, the required statements that the information in the subsequent or additional pies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.	
4.	Addition	nal comments:	

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-8,10-22

No: Claims

Inventive step (IS)

Yes: Claims

1-8, 10-22

No: Claims

Industrial applicability (IA)

Yes: Claims

1-8, 10-22

No: Claims

2. Citations and explanations

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

## Re Item V.

Independent claim 1 of the present application is directed to chiral ligands being orthosubstituted and in which the ortho substituent has the formula  $WR^1R^2$ .  $R^1$  and  $R^2$  are different from each other.

Numerous prior art documents are referred to in the description; see pages 1-8. None of these citations as well as the 3 closest prior art documents of the search report (which are equivalent to or correspond to documents mentioned in the description) disclose metallocens which display the aforementioned feature. Hence, claim 1 is novel.

Claim 1 is also inventive because there no suggestion in the prior art to make available metallocens as ligands for catalysis which exhibit 3 or 4 elements of chirality as defined in the description at page 8 and one element of chirality is based on the aforementioned distinguishing feature WR<sup>1</sup>R<sup>2</sup>.

Claims 10, 13, 20 and 22 relate to the use or preparation of new and inventive compounds. These claims are also acceptable with respect to Decision T 119/82 (see headnote 1).

Dependent claims 2-8, 11,12, 14-19 and 21 define further embodiments and likewise meet the requirements of the PCT.

## Re Item VIII.

Claim no. 9 is missing